On Monday, 10x Genomics Inc (NASDAQ: TXG) opened higher 4.06% from the last session, before settling in for the closing price of $10.34. Price fluctuations for TXG have ranged from $9.27 to $39.30 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 21.90%. Company’s average yearly earnings per share was noted 1.75% at the time writing. With a float of $101.42 million, this company’s outstanding shares have now reached $108.24 million.
Considering the fact that the conglomerate employs 1306 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 68.73%, operating margin of -31.51%, and the pretax margin is -29.09%.
10x Genomics Inc (TXG) Insider Activity
A key investor’s attitude towards the stock of the Health Information Services industry is another important factor to consider. The insider ownership of 10x Genomics Inc is 17.07%, while institutional ownership is 79.44%. The most recent insider transaction that took place on Feb 28 ’25, was worth 84,393. In this transaction Chief Executive Officer of this company sold 7,942 shares at a rate of $10.63, taking the stock ownership to the 871,540 shares. Before that another transaction happened on Feb 28 ’25, when Company’s Director, CEO proposed sale 7,942 for $10.57, making the entire transaction worth $83,947.
10x Genomics Inc (TXG) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.47% during the next five years compared to -36.10% drop over the previous five years of trading.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
Check out the current performance indicators for 10x Genomics Inc (TXG). In the past quarter, the stock posted a quick ratio of 4.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.52, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.15 in one year’s time.
Technical Analysis of 10x Genomics Inc (TXG)
Compared to the last year’s volume of 2.79 million, its volume of 2.68 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 37.77%. Additionally, its Average True Range was 0.88.
During the past 100 days, 10x Genomics Inc’s (TXG) raw stochastic average was set at 16.67%, which indicates a significant decrease from 56.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 91.26% in the past 14 days, which was higher than the 66.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.16, while its 200-day Moving Average is $17.26. Nevertheless, the first resistance level for the watch stands at $10.99 in the near term. At $11.23, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.58. If the price goes on to break the first support level at $10.40, it is likely to go to the next support level at $10.05. Should the price break the second support level, the third support level stands at $9.81.
10x Genomics Inc (NASDAQ: TXG) Key Stats
There are currently 122,302K shares outstanding in the company with a market cap of 1.32 billion. Presently, the company’s annual sales total 610,790 K according to its annual income of -182,630 K. Last quarter, the company’s sales amounted to 165,020 K and its income totaled -49,030 K.
